Biogen Inc. is taking on the development of a pair of Alzheimer’s disease drugs, but is splitting the risk by teaming up with Japan’s Eisai Inc. The pair announced March 5 that they will collaborate on the development and commercialization of up to four compounds with the potential to be disease modifying for the debilitating memory disease.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?